315 related articles for article (PubMed ID: 23888949)
21. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
22. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Nakagawa H; Sotamaa K; Prior TW; Westman J; Panescu J; Fix D; Lockman J; Comeras I; de la Chapelle A
N Engl J Med; 2005 May; 352(18):1851-60. PubMed ID: 15872200
[TBL] [Abstract][Full Text] [Related]
23. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC).
Newton K; Jorgensen NM; Wallace AJ; Buchanan DD; Lalloo F; McMahon RF; Hill J; Evans DG
J Med Genet; 2014 Dec; 51(12):789-96. PubMed ID: 25280751
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome.
Mas-Moya J; Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
Hum Pathol; 2015 Nov; 46(11):1616-25. PubMed ID: 26319271
[TBL] [Abstract][Full Text] [Related]
25. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome.
Rahner N; Friedrichs N; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
J Pathol; 2008 Jan; 214(1):10-6. PubMed ID: 17973250
[TBL] [Abstract][Full Text] [Related]
26. Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.
Case AS; Zighelboim I; Mutch DG; Babb SA; Schmidt AP; Whelan AJ; Thibodeau SN; Goodfellow PJ
Gynecol Oncol; 2008 Feb; 108(2):438-44. PubMed ID: 18022218
[TBL] [Abstract][Full Text] [Related]
27. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
[TBL] [Abstract][Full Text] [Related]
28. EPM2AIP1 Immunohistochemistry Can Be Used as Surrogate Testing for MLH1 Promoter Methylation in Endometrial Cancer.
Mrkonjic M; Turashvili G
Am J Surg Pathol; 2022 Mar; 46(3):376-382. PubMed ID: 34772843
[TBL] [Abstract][Full Text] [Related]
29. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.
Bouzourene H; Hutter P; Losi L; Martin P; Benhattar J
Fam Cancer; 2010 Jun; 9(2):167-72. PubMed ID: 19949877
[TBL] [Abstract][Full Text] [Related]
30. Initial screening by immunohistochemistry is effective in universal screening for Lynch syndrome in endometrial cancer patients: a prospective observational study.
Tsuruta T; Todo Y; Yamada R; Kuwahara K; Kurosu H; Minowa K; Minoura Y; Minobe S; Suzuki H; Kato H
Jpn J Clin Oncol; 2022 Jul; 52(7):752-758. PubMed ID: 35438162
[TBL] [Abstract][Full Text] [Related]
31. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach.
Hartman DJ; Brand RE; Hu H; Bahary N; Dudley B; Chiosea SI; Nikiforova MN; Pai RK
Hum Pathol; 2013 Nov; 44(11):2518-28. PubMed ID: 24034859
[TBL] [Abstract][Full Text] [Related]
32. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
Jin W; Wang LQ; Liu Y; Liu AJ
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
[No Abstract] [Full Text] [Related]
33. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
34. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
[TBL] [Abstract][Full Text] [Related]
35. Lynch syndrome in women less than 50 years of age with endometrial cancer.
Matthews KS; Estes JM; Conner MG; Manne U; Whitworth JM; Huh WK; Alvarez RD; Straughn JM; Barnes MN; Rocconi RP
Obstet Gynecol; 2008 May; 111(5):1161-6. PubMed ID: 18448750
[TBL] [Abstract][Full Text] [Related]
36. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
[TBL] [Abstract][Full Text] [Related]
37. Microsatellite instability: an update.
Yamamoto H; Imai K
Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
[TBL] [Abstract][Full Text] [Related]
38. Identification of new cases of early-onset colorectal cancer with an MLH1 epimutation in an ethnically diverse South African cohort.
Hitchins MP; Owens SE; Kwok CT; Godsmark G; Algar UF; Ramesar RS
Clin Genet; 2011 Nov; 80(5):428-34. PubMed ID: 21375527
[TBL] [Abstract][Full Text] [Related]
39. Risk of cancer in cases of suspected lynch syndrome without germline mutation.
Rodríguez-Soler M; Pérez-Carbonell L; Guarinos C; Zapater P; Castillejo A; Barberá VM; Juárez M; Bessa X; Xicola RM; Clofent J; Bujanda L; Balaguer F; Reñé JM; de-Castro L; Marín-Gabriel JC; Lanas A; Cubiella J; Nicolás-Pérez D; Brea-Fernández A; Castellví-Bel S; Alenda C; Ruiz-Ponte C; Carracedo A; Castells A; Andreu M; Llor X; Soto JL; Payá A; Jover R
Gastroenterology; 2013 May; 144(5):926-932.e1; quiz e13-4. PubMed ID: 23354017
[TBL] [Abstract][Full Text] [Related]
40. Relationship of lower uterine segment cancer with Lynch syndrome: a novel case with an hMLH1 germline mutation.
Masuda K; Banno K; Hirasawa A; Yanokura M; Tsuji K; Kobayashi Y; Kisu I; Ueki A; Nomura H; Tominaga E; Susumu N; Aoki D
Oncol Rep; 2012 Nov; 28(5):1537-43. PubMed ID: 22940821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
